Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism

Trial Profile

Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism; Venous thrombosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms EINSTEIN-CHOICE
  • Sponsors Bayer
  • Most Recent Events

    • 30 Oct 2017 According to a Janssen media release, based on the data from this trial the U.S. FDA approved the 10 mg once-daily dose of XARELTO (rivaroxaban) for reducing the continued risk for recurrent venous thromboembolism (VTE) after completing at least six months of initial anticoagulation therapy under a FDA Priority Review.
    • 19 Oct 2017 According to a Janssen media release, based on the data from this trial, European Commission has granted the approval to update the label for its oral Factor Xa inhibitor Xarelto (rivaroxaban) XARELTO label to include the 10 mg once-daily dose in the European Union.
    • 15 Sep 2017 Based on the data from this trial, the CHMP of the EMA has granted a positive opinion to update the label for its oral Factor Xa inhibitor Xarelto (rivaroxaban) to include a 10 mg once daily dose for the extended prevention of recurrent venous thromboembolism (VTE) and the label update will apply to patients who have already received at least six months of standard anticoagulation therapy, as reported in a Bayer media release. The final European Commission decision is expected by November 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top